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Macrovascular and microvascular diseases are currently the principal causes of morbidity and mortality in subjects with diabe-
tes. Disorders of the physiological signaling functions of reactive oxygen species (superoxide and hydrogen peroxide) and reac-
tive nitrogen species (nitric oxide and peroxynitrite) are important features of diabetes. In the absence of an appropriate com-
pensation by the endogenous antioxidant defense network, increased oxidative stress leads to the activation of stress-sensitive in-
tracellular signaling pathways and the formation of gene products that cause cellular damage and contribute to the vascular 
complications of diabetes. It has recently been suggested that diabetic subjects with vascular complications may have a defective 
cellular antioxidant response against the oxidative stress generated by hyperglycemia. This raises the concept that antioxidant 
therapy may be of great benefit to these subjects. Although our understanding of how hyperglycemia-induced oxidative stress 
ultimately leads to tissue damage has advanced considerably in recent years, effective therapeutic strategies to prevent or delay 
the development of this damage remain limited. Thus, further investigation of therapeutic interventions to prevent or delay the 
progression of diabetic vascular complications is needed. 
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INTRODUCTION
Diabetes diagnoses are increasing at an alarming rate world-
wide. The majority of diabetes-related deaths arise from vas-
cular complications such as myocardial infarction, cerebrovas-
cular disease, and peripheral vascular disease [1]. Large pro-
spective randomized clinical studies show that long-term gly-
cemic control is an important predictor of diabetic vascular 
complications [1,2]. 
  There is considerable evidence that many of the biochemi-
cal pathways adversely affected by hyperglycemia including 
glucose oxidation, the formation of advanced glycation end-
products (AGE), and activation of polyol pathways, are associ-
ated with the generation of reactive oxygen species (ROS), ul-
timately leading to increased oxidative stress in a variety of tis-
sues [3]. In the absence of an appropriate compensation by the 
endogenous antioxidant defense network, increased oxidative 
stress leads to the activation of stress-sensitive intracellular 
signaling pathways and the formation of gene products that 
cause cellular damage and contribute to the late complications 
of diabetes [3,4]. 
  Major reactive species, including ROS and reactive nitrogen 
species (RNS) consist of paramagnetic free radicals (superox-
ide O2•-, hydroxyl HO•, peroxy ROO•, and nitric oxide free 
radical NO•) and diamagnetic molecules (hydrogen peroxide 
H2O2 and peroxynitrite ONOO
-) which are products of the re-
actions of these free radicals. All these species were previously 
considered to be toxic agents capable of damaging biomole-
cules. However it is now known that physiological free radicals 
superoxide and nitric oxide are relatively harmless species that 
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are able to initiate or mediate many enzyme- and gene-depen-
dent reactions in both physiological and pathophysiological 
processes. Increasing evidence in experimental and clinical 
studies suggests that ROS/RNS play important roles in the 
pathogenesis of diabetic vascular diseases [4].
  This review summarizes recent knowledge on the relevance 
of oxidative and nitrosative stress in the pathophysiology of 
diabetic vascular complications.
REACTIVE OXYGEN SPECIES SIGNALING IN 
DIABETES
Sources of ROS 
As the development of diabetes mellitus is characterized by 
high serum glucose levels, this prooxidant molecule can be an 
origin of ROS overproduction (Fig. 1). High glucose (HG) lev-
els can initiate the production of superoxide and hydrogen 
peroxide, precursors of reactive free radicals, which are able to 
stimulate the decline of antioxidant systems, directly damage 
many biomolecules, and increase lipid peroxidation in diabe-
tes [5,6]. 
  The most important sources of ROS under hyperglycemic 
conditions are mitochondria and NAD(P)H oxidases. Hyper-
glycemia decreases glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) activity in bovine aortic endothelial cells via 
the increased production of mitochondrial superoxide and a 
concomitant increase in hexosamine pathway activity [7,8]. 
Mitochondrial ROS have also been implicated in diabetic 
complications and progression of the underlying diabetic state; 
however, it is not clear whether mitochondria of diabetic origin 
actually generate ROS independent of the surrounding dia-
betic milieu.
  NAD(P)H oxidases are another important ROS source in 
diabetes. Superoxide production significantly increases by up-
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Fig. 1. Induction of reactive oxygen species (ROS)/reactive nitrogen species (RNS) formation by hyperglycemia in diabetes. The 
major enzymes responsible for ROS generation in the vasculature include NAD(P)H oxidase, xanthine oxidase, and uncoupled 
nitric oxide synthase (NOS). The absence of an appropriate compensation by the endogenous antioxidant defense network and 
increased oxidative stress leads to the activation of stress-sensitive intracellular signaling pathways and the formation of gene 
products that cause cellular damage and contribute to the late complications of diabetes. AGE, advanced glycation end-products; 
PKC, protein kinase C; SOD, superoxide dismutase; GSH, reduced glutathione; GSSG, oxidized glutathione.192
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regulated NAD(P)H oxidase and endothelial NO synthase in 
human blood vessels from subjects with type 2 diabetes [9]. 
These effects of NAD(P)H oxidase and uncoupling eNOS might 
be mediated by protein kinase C (PKC) signaling. Our group 
assumed that the enhanced proliferative capacity of diabetic 
vascular smooth muscle cells (VSMC) is a consequence of 
NAD(P)H oxidase activation stimulated by the activation of a 
protein tyrosine kinase [10]. It has been suggested that ROS 
formation by HG-stimulated NAD(P)H oxidase can also up-
regulate antioxidant enzymes [11]. Therefore NAD(P)H oxi-
dase might be a double-edged sword, providing feedback de-
fense against excessive ROS generation through the activation 
of receptor tyrosine kinases and the redox-sensitive transcrip-
tion factor Nrf2-Keap1 signaling pathway [11]. It is of impor-
tance that Block et al. [12] have recently identified NAD(P)H 
oxidase (Nox4) as mitochondrial cytochrome c oxidase subunit 
IV as being an additional source of ROS in diabetes. It should 
be noted that xanthine oxidase is also a potential source of ROS 
formation in diabetes. 
ROS overproduction in diabetes
Diabetes causes increased oxidative stress in various tissues as 
evidenced by increased levels of oxidized DNA, proteins, and 
lipids. Besides damaging the functions of these molecules, oxi-
dative stress also triggers a series of cellular responses, includ-
ing the activation of PKC, NF-κB, and JNK stress-associated 
kinases [13]. Inappropriate activation of these important regu-
latory molecules can have deleterious effects on cellular func-
tions, and is thought to contribute to the pathogenesis of vari-
ous diabetic vascular complications. However, it is not clear 
how hyperglycemia leads to increased oxidative stress. Most 
likely, both the increased production of ROS and decreased 
capacity of the cellular antioxidant defense system combine to 
produce oxidative stress in diabetes. 
  Hyperglycemia increases oxidant production by multiple 
pathways rather than a single dominant pathway. Glucose can 
undergo non-enzymatic reactions to form gluco-oxidants and 
glycated products, which can be oxidants [13]. Metabolism of 
excessive intracellular glucose can occur by several processes 
such as aldose reductase, mitochondrial oxidative phosphory-
lation, activation of NAD(P)H oxidases, and alteration of 
NADPH/NADP ratios [3]. Among these possibilities, recent 
work has centered on mitochondrial metabolism and activation 
of NAD(P)H oxidases [3,13]. It has been suggested that most 
glucose-induced oxidants are derived from overproduction of 
superoxide by the mitochondrial electron-transport chain [3]. 
By-products of this process will trigger signaling cascades 
such as activation of PKC, production of hexosamine, in-
creased flux via aldose reductase, and production of glycated 
products. However, other investigators have reported that high 
glucose levels can activate NAD(P)H oxidases in vascular cells 
independent of mitochondrial metabolism [14]. It is known 
that the ROS activation of PKC stimulates subsequent ROS 
overproduction; therefore this enzymatic cascade can be an 
important harmful signaling process in hyperglycemia and di-
abetes. Thus, Koya and King [15] suggested that glucose’s ad-
verse effects in diabetes and hyperglycemia might be a conse-
quence of ROS-stimulated activation of the diacylglycerol 
(DAG)/PKC enzymatic pathway because treatment with 
α-tocopherol prevented glucose-induced vascular dysfunc-
tions and inhibited DAG/PKC activation. ROS signaling is also 
an important stimulus of harmful enzymatic cascades cata-
lyzed by protein kinase Akt/B [16]. 
  Recently, two other aspects have been found to be related to 
glucose-induced oxidative stress. First, several studies have 
suggested that intermittent low and high glucose conditions (a 
condition known as “glucose variability”) are even more dele-
terious to endothelial cell function than a steady, constant in-
crease in glucose [17]. These conditions also induce endotheli-
al cells to enter into a proinflammatory state, and this state is 
associated with the upregulation of various adhesion molecules 
and proinflammatory cytokines [17]. Some of the pathways 
implicated in these exacerbated cellular responses, involve ac-
tivation of PKC, NAD(P)H oxidases, and mitochondrial oxi-
dants. Secondly, it has been shown in culture and in diabetic 
rats that endothelial cells exhibit a persistence or ‘memory’ of 
induced basement membrane mRNA expression long after 
normalization of high glucose levels, a condition called “glu-
cose memory” [18]. This finding suggests that glucose induces 
long-lasting deleterious effects that persist beyond the period 
of hyperglycemia.
  Abundant evidence exists that many protein, lipid, and DNA 
markers of oxidative stress are increased in cultured vascular 
cells exposed to high glucose levels and in vascular tissues from 
animals and human subjects with diabetes [13]. In cultured 
vascular cells, elevating glucose levels in the media increases 
the production of oxidants such as gluco-oxidants, glycated 
compounds, oxidized low density lipoprotein (LDL), superox-
ide, and nitrotyrosine [14]. Similarly, elevated levels of isopros-
tanes, 8-hydroxydeoxyguanosine, and lipid peroxides have 193
Oxidative stress and diabetic vascular diseases
Diabetes Metab J 2012;36:190-198 http://e-dmj.org
been reported in diabetic animals and in human subjects with 
diabetes [14]. Although numerous reports have substantiated 
that oxidant production is increased in diabetes, clinical evi-
dence for tissue damage as a result of oxidative stress has not 
been clearly demonstrated because both plasma and cells con-
tain a large reserve of antioxidants. In fact, the levels of various 
antioxidants in plasma and cells have not consistently been 
shown to decrease in diabetic states [14]. 
Role of ROS in development of macrovascular 
complications 
Abnormalities in endothelial and vascular smooth muscle cell 
function, as well as the coagulation system, contribute to vas-
cular complications in diabetes. 
Vascular endothelial dysfunction
Endothelial cells modulate vascular function and structure. In 
normal endothelial cells, nitric oxide is synthesized and released 
to maintain vascular homeostasis. Clinical studies have con-
sistently found that endothelium-dependent vasodilation is 
abnormal in subjects with diabetes [15]. The major contribu-
tor to endothelial oxidative stress is the increased production 
of superoxide. This seems to occur via two principal sources: 
NAD(P)H oxidases and uncoupled endothelial nitric oxide 
synthase (eNOS). Hyperglycemia, AGE, free fatty acid (FFA), 
and oxidized LDL have been shown to increase endothelial 
NAD(P)H oxidase activity and the activation of NAD(P)H 
oxidases by hyperglycemia and FFA has been shown to be me-
diated by PKC [16]. Vessels isolated from diabetic subjects ex-
hibit increased superoxide production that is inhibited by di-
phenylene iodinium, and demonstrate increased expression of 
several NAD(P)H oxidase subunits (p22phox, p47phox, and 
p67phox) [17], suggesting that NAD(P)H oxidases are more 
active in diabetes. Not only does excess superoxide itself cause 
increased oxidative stress, but it can also react with nitric ox-
ide (NO•) to produce peroxynitrite [18], which, in turn, can 
oxidize tetrahydrobiopterin (BH4), thus reducing its availabili-
ty to eNOS [17,18]. In the presence of reduced concentrations 
of BH4, eNOS becomes uncoupled and transfers electrons to 
molecular oxygen instead of L-arginine to produce superoxide 
rather than NO•. The presence of uncoupled eNOS in the dia-
betic vasculature is supported by a study in which diabetic ves-
sels were found to produce less superoxide when incubated 
with the NO• synthase inhibitor NG-nitro-L-arginine methyl 
ester [17]. BH4 availability may also be decreased by a reduc-
tion of its synthesis. The expression of GTP-cyclohydrolase I 
(GTPCH), the rate-limiting enzyme for de novo BH4 synthesis, 
is reduced in diabetic rats [19]. Furthermore, transgenic mice 
overexpressing GTPCH treated with streptozotocin (STZ) are 
able to maintain endothelial function [19]. Clinical studies 
have demonstrated that BH4 supplementation given to diabet-
ic subjects improves their endothelium-dependent vasodila-
tion, indicating that uncoupled eNOS plays a role in diabetic 
endothelial dysfunction [17-19]. 
  An additional effect of high serum glucose levels is delayed 
replication of large-vessel endothelium. Superoxide dismutase, 
catalase, and reduced glutathione protect human endothelial 
cells from glucose-induced delay in replication, offering further 
evidence of the importance of oxidative stress in diabetes [20]. 
Vascular smooth muscle dysfunction 
In type 2 diabetic subjects, the vasodilator response to endog-
enous nitric oxide donors is diminished [15,20], suggesting 
that there is a fundamental abnormality in VSMC function. 
The oxidative stress produced in VSMC in diabetes may shift 
them from a contractile to a proliferative phenotype, thus fur-
ther inhibiting vasodilation and enhancing lesion formation. 
Subjects with diabetes have increased proliferation and migra-
tion of VSMC into atherosclerotic lesions [21]. There are a 
number of studies showing that exposure of VSMC to high 
glucose conditions results in oxidative stress and subsequent 
cell proliferation.
  Hyperglycemia causes PKC activation and subsequent ROS 
production via NAD(P)H oxidase in cultured aortic smooth 
muscle cells [14]. In STZ-treated rats, a p22phox-containing 
NAD(P)H oxidase was found to be a mediator of VSMC pro-
liferation [22]. Additionally, the polyol pathway has been im-
plicated in hyperglycemia-induced, PKC-directed NF-κB acti-
vation, as inhibition of aldose reductase is able to mitigate 
both PKC and NF-κB activation in cultured rat aortic smooth 
muscle cells [23]. Despite the increased proliferation and mi-
gration of VSMC in subjects with diabetes [21], atherosclerot-
ic lesions from these patients have fewer VSMC, suggesting 
that VSMC death potentially plays a role in plaque instability 
and subsequent rupture [24]. A study in human aortic smooth 
muscle cells revealed that high glucose conditions cause cell 
necrosis via hydrogen peroxide [24]. Additionally, oxidized 
LDL is able to induce VSMC apoptosis via ROS and may be 
increased in diabetic subjects [24]. 
  In diabetic subjects, the elaboration of cytokines diminishes 194
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synthesis collagen of vascular smooth muscle and increases 
production of matrix metalloproteinases, which may also lead 
to an increased tendency for plaque destabilization and rup-
ture [21,24].
Role of ROS in development of microvascular 
complications
The microvascular complications of diabetes, including ne-
phropathy, retinopathy and neuropathy, are common manifes-
tations of diabetes. Although the mechanisms underlying the 
development of these conditions are incompletely understood, 
oxidative stress has been implicated. In isolated kidneys, expo-
sure to ROS causes a drastic dose-dependent decrease in de 
novo synthesis of heparan sulfate, an effect that is reversed by 
catalase [25]. In addition, the ability of glomeruli isolated from 
STZ-induced diabetic rats to degrade hydrogen peroxide is 
greatly impaired; this has been attributed to either decreased 
catalase activity or altered glutathione redox cycling [25]. Re-
cent data has shown that the expression of the NAD(P)H oxi-
dase subunits Nox4 and p22phox are upregulated in the kid-
ney of STZ-induced diabetic rats and that NAD(P)H oxidase-
dependent production of ROS may cause DNA damage in dia-
betic renal tissues leading to the development of nephropathy 
[26].
  Evidence for the participation of oxidative stress in the 
pathogenesis of diabetic retinopathy is scant and limited to 
studies published in abstract form. One report showed that 
the activity of NAD(P)H oxidase was increased in the retina of 
diabetic rats and that this might be involved in the development 
of diabetic retinopathy [27]. 
  Stronger evidence exists for an involvement of ROS in the 
etiology of early experimental diabetic neuropathy. One report 
showed that probucol treatment prevents the reduction in 
nerve conduction velocity in STZ-induced diabetic rats and in 
normal rats treated with primaquine. The authors suggested 
that nerve dysfunction depends on oxidative stress that causes 
neurovascular defects resulting in endoneural hypoxia [28]. 
Treatment with the transition-metal chelating agents deferox-
amine and trientine, which can prevent auto-oxidation, cor-
rected nerve conduction and blood flow changes that occurred 
2 months after the induction of diabetes in this model [28]. 
RNS SIGNALING IN DIABETES
Nitric oxide is an endothelium-derived relaxing factor (EDRF) 
and its role is very important in the normal activity of cells. 
Therefore, it might be expected that as in other pathological 
states a decrease in nitric oxide can take place in diabetes. On 
the other hand, nitric oxide is soluble in aqueous and lipid me-
dia and it rapidly diffuses through the cytoplasm and plasma 
membranes. In an inflammatory state, such as obesity, the im-
mune system produces both superoxide and nitric oxide, which 
may react together to produce significant amounts of peroxyni-
trite anion (ONOO
-). Peroxynitrite is a potent oxidizing agent 
that can cause DNA fragmentation and lipid peroxidation [29]. 
There are multiple lines of evidence demonstrating the forma-
tion of peroxynitrite in diabetic vasculature, both in experi-
mental models and in humans [30,31]. The tissues and species 
in which peroxynitrite has been identified in experimental an-
imals and in humans include plasma, kidney, blood vessels, 
retina, heart and peripheral nerves and have been overviewed 
recently [30]. The mechanisms that underlie peroxynitrite-in-
duced diabetic complications and vascular alterations are mul-
tiple [31,32]. One of the important pathways of peroxynitrite-
mediated vascular dysfunction in diabetes involves activation 
of the nuclear enzyme poly(ADP-ribose) polymerases (PARP 
enzymes). Activated PARP-1 cleaves NAD
+ into nicotinamide 
and ADPribose and polymerizes the latter on nuclear acceptor 
proteins. Peroxynitrite-induced overactivation of PARP con-
sumes NAD
+ and consequently ATP culminating in cell dys-
function, apoptosis or necrosis [33]. Thus Langenstroer and 
Pieper [34] found that spontaneous EDRF released in diabetic 
rat aorta can be unmasked by the addition of superoxide dis-
mutase (SOD) because SOD produces a significantly greater 
relaxation in diabetic aorta compared to control aorta. It means 
that NO synthases in diabetes produce superoxide in an un-
coupled state. Other authors have also suggested that peroxyni-
trite formed by uncoupled NO synthases in human blood ves-
sels from subjects with diabetes type 2 can be a mediator of the 
cytotoxic effects of high glucose [35].
TRIALS OF ANTIOXIDANT THERAPY FOR 
DIABETIC VASCULAR COMPLICATIONS
Many trials in diabetic subjects and animal models of diabetes 
have attempted to determine whether antioxidant treatments 
can prevent or delay the onset of diabetic complications.
  If the effects of ROS/RNS signaling in enzyme/gene pro-
cesses depend on the levels of ROS/RNS production, then 
ROS/RNS-induced damage in diabetes as well in the other pa-195
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thologies such as cardiovascular diseases, inflammation, and 
aging cannot be successfully inhibited by the traditional anti-
oxidants vitamin C or vitamin E which are unable to react with 
superoxide [36,37]. Nonetheless some aforementioned data 
demonstrate the successful application of various antioxidants 
and free radical scavengers for suppression of damaging pro-
cesses in diabetes.
Experimental animal trials
Several antioxidants have been studied in diabetic and insulin-
resistant animals, mostly rodents, with respect to their ability 
to correct vascular and neurologic dysfunction [28]. 
  α-Lipoic acid is needed to regenerate glutathione and oxi-
dized vitamins C and E. In animal studies, vitamins C and E 
and α-lipoic acid improve nerve conduction velocity and blood 
flow to the peripheral nerves, reduce retinal leukocyte adhe-
sions, and improve cataract formation, suggesting that they 
may be an effective treatment of diabetic complications [28,38]. 
Furthermore, vitamins C and E, either individually or in com-
bination, normalize many parameters of oxidative stress such 
as lipid peroxidation, isoprostane production, plasma malo-
ndialdehyde, and NF-κB activation in diabetic animals [39]. 
Besides biochemical changes, many early or functional mark-
ers of diabetic retinopathy, nephropathy, neuropathy, and even 
cardiovascular disease have been reported to be prevented or 
reversed by antioxidants, including blood flow, nerve conduc-
tion velocity, permeability, endothelial dysfunction, albumin-
uria, and vascular contractility [38]. A few reports have indi-
cated that vitamins C and E may even prevent late pathologi-
cal changes in the retina and peripheral nerves of diabetic ani-
mals [39]. 
  PKC inhibitors may also function as antioxidants via their 
inhibitory effect on hyperglycemia-induced activation of 
NAD(P)H oxidase. These experiments only indirectly impli-
cate oxidative stress, however, since PKC likely regulates dia-
betic complications on multiple levels. Oral administration of 
roboxistaurin (LY333531), a specific PKC-β inhibitor, to dia-
betic rats prevents increased albumin excretion, elevated glo-
merular filtration, and abnormal retinal hemodynamics [14]. 
Consistent with this, one report showed that angiotensin con-
verting enzyme (ACE) inhibitors and angiotensin receptor 
blockers prevent the development of albuminuria in STZ-in-
duced diabetic rats in parallel with prevention of increased ex-
pression of the p47phox component of NAD(P)H oxidase and 
production of its oxidative products [40]. 
Human clinical trials
Most clinical studies on the effects of antioxidant treatments 
have used early surrogate markers and are limited in duration 
and sample size. 
  A small, short-term single blind study showed that admin-
istration of an antioxidant mixture (N-acetylcysteine, vitamin 
E, and vitamin C) to control subjects, as well as subjects with 
type 2 diabetes and impaired glucose tolerance reduced the 
increase in oxidants and endothelial markers evoked by a fatty 
meal [41]. Another, short-term, but randomized double blind, 
placebo controlled study examined the effects of vitamins E 
and C with or without zinc and magnesium and demonstrated 
reduced albumin excretion, along with evidence of reduced 
lipid peroxidation in groups receiving the vitamins [42]. Al-
though many clinical trials with such antioxidant vitamins in-
vestigating the progression of diabetic complications conclude 
as negative or inconclusive, one may wish to see additional 
studies, perhaps involving a combination of these vitamins, or 
mega-dose therapies. 
  Studies using α-lipoic acid suggest that it may improve the 
symptoms of diabetic polyneuropathy [13]. α-lipoic acid has 
the additional property of increasing glucose transport in 
muscle cells, which may be related to its antioxidant properties 
[13]. Clinical trials are now ongoing to assess the effects of 
PKC-β inhibition on diabetic retinopathy and neuropathy. 
The beneficial effects of a PKC-β specific inhibitor might also 
partly due to its inhibition of ROS production [14]. Further 
investigation into the antioxidant properties of this agent is 
necessary. 
  Importantly, pharmacologic agents currently in use that 
have been shown to be effective in reducing cardiovascular 
mortality are known to have antioxidant properties. ACE in-
hibitors and HMG-CoA reductase inhibitors or statins have 
already demonstrated beneficial effects on diabetic subjects in 
large randomized controlled-trials [43]. Interestingly, ACE in-
hibitors, which act partially to prevent the pro-oxidant effects 
of angiotensin II, were shown to prevent the onset of type 2 di-
abetes in the Heart Outcomes Prevention Evaluation Study 
[43]. Statins have been shown to exert vascular antioxidative 
properties [44]. 
Recent approaches to antioxidant therapy
The use of new antioxidant agents that penetrate specific cel-
lular compartments may provide a new approach to dealing 
with oxidative stress in diabetes. Agents such as idebenone 196
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andmito-Q, which are selectively taken up into mitochondria 
should be searched further [45,46]. Edaravone, 3-methyl-1-
phenyl-2-pyrazolin-5-one, is a novel scavenger of free radicals 
[47] and has been shown to ameliorate renal ischemia/reper-
fusion injury by scavenging free radicals produced in renal tu-
bular cells and inhibiting lipid peroxidation [48]. Mimetics of 
superoxide dismutase have been investigated in experimental 
models of diabetes. Tempol (4-hydroxy-2, 2, 6, 6-tetramethyl-
piperidine 1-oxyl) improved endothelial function in Zucker 
diabetic fatty rats and in db/db mice [49]. As NAD(P)H oxi-
dase is an important source of reactive oxygen species, target-
ing this enzyme may provide another approach to reducing 
the oxidative stress of diabetes and its consequences. Indeed, 
administration of the NAD(P)H oxidase assembly inhibitor 
apocynin attenuated the long-term effects of streptozotocin-
induced diabetes in producing albuminuria and glomerulo-
sclerosis [50]. Resveratrol is a polyphenol phytoalexin that can 
reduce vascular superoxide levels [51] and restore endothelial 
function in type 2 diabetes by inhibiting tumor necrosis fac-
tor-alpha induced activation of NAD(P)H oxidase and pre-
serving eNOS phosphorylation [52]. NF-E2-related factor-2 
(Nrf2) is a transactivator of genes that contain an antioxidant 
response element in their promoter. Such genes code for a 
number of enzymes including NADPH:quinone oxidoreduc-
tase, glutathione S-transferases and aldo-keto reductases, that 
have an important role in the protection of cells against oxida-
tive stress [52]. 
CONCLUSIONS
The present paper is a review of published studies on the role 
of ROS/RNS in the pathogenesis of diabetic vascular compli-
cations. A large number of studies indicate that oxidant pro-
duction is clearly increased through multiple pathways as a re-
sult of hyperglycemia. It has recently been suggested that dia-
betic subjects with vascular complications may have a defec-
tive cellular antioxidant response against the oxidative and ni-
trosative stress generated by hyperglycemia. This raises the 
concept that antioxidant therapy may be of great benefit to 
these subjects. However, supportive evidence that antioxidants 
can provide beneficial effects on diabetic vascular complica-
tions in large clinical studies is lacking, largely due to the lack 
of a suitable antioxidant supplement. Further initiatives to 
study the mechanisms that cause the generation of oxidative 
and nitrosative stress in diabetes may lead to the discovery and 
evaluation of new antioxidant molecules that could inhibit the 
diabetes-related oxidative and nitrosative stress mechanisms.
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